Copyright: ©Author(s) 2026.
World J Gastroenterol. Apr 7, 2026; 32(13): 115649
Published online Apr 7, 2026. doi: 10.3748/wjg.v32.i13.115649
Published online Apr 7, 2026. doi: 10.3748/wjg.v32.i13.115649
Figure 1 Study flow chart of patient selection.
PBC: Primary biliary cholangitis; T2DM: Type 2 diabetes mellitus.
Figure 2 Kaplan-Meier survival analysis for liver-related mortality according to lean type 2 diabetes mellitus phenotype.
A: Survival comparison among non-lean non-type 2 diabetes mellitus (T2DM), lean non-T2DM, non-lean T2DM, and lean T2DM groups (P < 0.001); B: Kaplan-Meier survival curves for non-lean non-T2DM and lean T2DM phenotype groups after propensity score matching. T2DM: Type 2 diabetes mellitus.
Figure 3 Forest plot showing hazard ratios and 95% confidence intervals for the stratified analysis of type 2 diabetes mellitus and lean interaction effects in primary biliary cholangitis patients.
T2DM: Type 2 diabetes mellitus.
Figure 4 Propensity score distributions before and after matching between lean type 2 diabetes mellitus and non-lean non-type 2 diabetes mellitus primary biliary cholangitis patients.
T2DM: Type 2 diabetes mellitus.
Figure 5 Covariate balance before and after propensity score matching between lean type 2 diabetes mellitus and non-lean non-type 2 diabetes mellitus groups.
Alb: Albumin; PLT: Platelet; TBil: Total bilirubin; AMA-M2: Anti-mitochondrial antibody M2; INR: International normalized ratio; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase.
- Citation: Yin TT, Lin HY, Zhou M, Li JW, Mo QL, Wang HJ, Chen J, Zhu HL, Li YT, Zheng MY, Yang JH. Lean type 2 diabetes mellitus is an independent predictor of mortality in primary biliary cholangitis. World J Gastroenterol 2026; 32(13): 115649
- URL: https://www.wjgnet.com/1007-9327/full/v32/i13/115649.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i13.115649
